Anticonvulsant hypersensitivity syndrome: Is there a role for immunomodulation? by Cumbo-Nacheli, Gustavo et al.
Anticonvulsant hypersensitivity syndrome: Is there a role
for immunomodulation?
*Gustavo Cumbo-Nacheli, *Jarrett Weinberger, *Michel Alkhalil, *Neelima Thati,
and yAlan P. Baptist
∗Department of Internal Medicine, Wayne State University, Detroit, Michigan, U.S.A.; and yDivision of Allergy
and Clinical Immunology, University of Michigan, Ann Arbor, Michigan, U.S.A.
SUMMARY
The anticonvulsant hypersensitivity syndrome
(AHS) is an idiosyncratic immunologic reaction
to certain anticonvulsant medications, in which
internal organ involvement may lead to fatal
multisystemic failure. This syndrome has been
associated with the use of aromatic ring-contain-
ing agents such as phenytoin, carbamazepine, or
phenobarbitone. Clinically, this condition
presents with the classic triad of fever, rash, and
lymphadenopathy. We review the existing litera-
ture on AHS pathogenesis and illustrate a case
complicated by liver dysfunction where the use
of N-acetylcysteine (N-AC) and intravenous
immunoglobulin (IVIG) may have altered the
course of the disease. The rationale of suggesting
N-AC and IVIG for the treatment of this syn-
drome relies on the theoretical synergistic
effects of the two agents. Although treatment
for this syndrome remains controversial and
relies heavily on anecdotal evidence, the progres-
sion of hepatic injury may be prevented by the
addition of N-AC. The scavenging properties of
N-AC may palliate and possibly prevent free rad-
ical-mediated liver damage. In addition, IVIG
may effectively modulate the overreactive
immune system in AHS. We discuss the possible
role of using immunomodulating agents for the
treatment of this syndrome and suggest that
alternative regimens should be given special con-
sideration especially in those critical clinical situ-
ations where supportive measures appear to be
unsuccessful.
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syndrome, N-acetylcysteine, Intravenous immu-
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Anticonvulsant hypersensitivity syndrome (AHS) is
one of the less known side effects of antiepileptic medi-
cations. It is described as an idiosyncratic immunologic
reaction against certain anticonvulsant agents. This syn-
drome should be considered in patients recently started
on phenytoin, carbamazepine, or phenobarbitone who
present with the classic triad of fever, rash, and lymph-
adenopathy (Barghava, 2001; Mason, 2007). The skin is
affected in nearly 90% of AHS cases, and ranges from a
mild exanthematous pruritic rash to severe exfoliating
dermatitis. The torso and extremities are most frequently
affected; palms and soles are usually spared. The cutane-
ous involvement is often synchronous with the onset of
the fever. The typical febrile pattern is intermittent and
can be found to be as high as 40C. Lymphadenopathy
is typically diffuse. If pharyngitis is present (10% of
cases), cervical lymph nodes may be prominent. Liver
damage is found in 50% of AHS cases and is an indica-
tor of poor prognosis. Infrequent clinical manifestations
include interstitial nephritis, myocarditis, colitis, myo-
arthralgias, and splenic rupture (Fervenza et al., 2000;
Zaidi, 2005; Korem et al., 2006). The clinical findings
of AHS can become clinically apparent 1 week after
exposure and up to 3 months after discontinuation of the
responsible agent.
AHS is often more severe in previously sensitized indi-
viduals. The mortality for AHS with hepatic failure has
been reported to be as high as 50%. The severity and prog-
nosis of the disease depends on the degree of internal
organ involvement. Early clinical recognition of the dis-
ease and prompt discontinuation of the offending drug are
essential in order to prevent adverse outcomes (Vittorio &
Muglia, 1995).
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Initial therapeutic approaches traditionally involve
cessation of any causative medication and aggressive
supportive measures: intravenous hydration, antihista-
mines, and corticosteroids (Morkunas & Miller, 1997;
Kennebeck, 2000; Knowles & Shear, 2007). In addition,
intravenous immunoglobulin (IVIG) may effectively
modulate the overreactive immune system in AHS (Scheu-
erman et al., 2001; Mostella et al., 2004). No prospective
randomized trials have assessed the efficacy of AHS treat-
ments; however, several reports describe the successful
immunomodulatory benefits of IVIG (Scheuerman et al.,
2001; Mostella et al., 2004; Li et al., 2005; Ting, 2007).
Although treatment for this syndrome remains contro-
versial and relies heavily on anecdotal evidence, it has been
suggested that progression of hepatic injury may be pre-
vented by the addition of N-acetylcysteine (N-AC). N-AC
scavenging properties may palliate and even further prevent
free radical-mediated liver damage (Ben-Ari et al., 2000).
The potential benefits and risks of N-AC administration in
patients with AHS have been documented. Based on the
nature of AHS, we postulate that a combination of IVIG
and N-AC administration work synergistically to attenuate
the immunopathic reactions seen in this disease.
Report of a Case
A 59-year-old African American female presented to
the emergency department with a chief complaint of a pru-
ritic rash. One month prior to her presentation, the patient
had been started on 300 mg oral phenytoin daily for the
treatment of a newly diagnosed seizure disorder. The rash
was first noticed 2 weeks prior to her hospital visit and
spread from her legs to the torso, arms, and face. In addi-
tion, the patient complained of neck fullness, dysphagia,
and decreased appetite. She complained of a subjective
fever but denied any other symptoms. Her past medical
history was significant for essential hypertension, emphy-
sema, and dyslipidemia. Her medications included oral
lisinopril 10 mg daily, inhaled tiotropium 18 lg daily, and
inhaled albuterol as needed. The patient denied the use of
illegal substances. Her past family history was unremark-
able. No drug or environmental allergies were reported.
On presentation to the emergency department, her tem-
perature was 38.8C, blood pressure 140/83 mmHg, respira-
tions 18 per minute, and a pulse of 117 beats per minute. On
physical exam, the rash predominated on her extremities
and torso. The lesions were erythematous, raised, diffuse,
and nonblanching. There was minimal oral mucosal enant-
hema. There was palpable bilateral anterior cervical lymph-
adenopathy. These lymph nodes were indurated, tender, and
enlarged. The abdominal exam was benign, without hepato-
splenomegaly. The rest of the exam was unremarkable.
Initial liver tests showed: alkaline phosphatase (ALP)
510 UI/L (reference range 50–180 UI/L), alanine amino-
transferase (ALT) 331 UI/L (reference range 0–65 UI/L),
aspartate aminotransferase (AST) 109 UI/L (reference
range 0–60 UI/L). A skin biopsy was performed and dem-
onstrated an inflammatory infiltrate that was predomi-
nantly perivascular and lymphocytic in nature. There were
no vasculitic features or necrosis, making the diagnosis of
Stevens-Johnson syndrome or toxic epidermal necrolysis
(TEN) less likely. Based on these clinical findings and the
biopsy results, AHS was diagnosed. Her anticonvulsant
medications were immediately discontinued. The patient
received IV fluid hydration, corticosteroids, and antihista-
mines. On hospital day 4, her AST was 174 UI/L and ALT
71UI/L. She was discharged on a 5-day methylpredniso-
lone taper (32 mg on day 1, 16 mg on day 2, 8 mg on day
3, 4 mg on day 4, and 2 mg on day 5). She was instructed
to discontinue the phenytoin.
Five days after the initial discharge, the patient returned
to the emergency department. At this time the patient com-
plained of worsening rash, generalized increased pruritus,
and diffuse abdominal discomfort. Admission temperature
was 38.6C, heart and respiratory rate 114 and 26 per
minute, respectively. Her lips were swollen, although there
was no edema or airway compromise present. The skin
lesions were erythematous, maculopapular, and tender to
palpation (Figs. 1 and 2). These affected areas were
nonconfluent, global, and diffuse. Her oral mucosa was
spared. White blood cell count was 16,200 cells/L (refer-
ence range 3,500–10,600 cells/L), ALP 402 UI/L, ALT 226
UI/L, and AST 257 UI/L. A drug screen was negative, and
the phenytoin level was undetectable. Initial treatment
included IV fluids, IV corticosteroids, and antihistamines.
The patient’s respiratory status and liver enzymes wors-
ened. On hospital day 5, she was admitted to the ICU for
respiratory compromise and impending hepatic failure.
She continued to require supplemental oxygen and aggres-
sive fluid resuscitation. On hospital day 6, the AST and
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ALT levels were above the upper limit of measurement
(>3000 UI/L). The liver function and overall clinical
picture continued to decline. Given the severity of the
situation, the decision to start N-AC and IVIG was made.
The IVIG was administered at 1 g/kg daily for 2 days. The
loading dose for IV N-AC was 150 mg/kg IV in 200 mL
5% dextrose over 60 min. After the initial dose, the infusion
was maintained at 50 mg/kg IV in 500 mL 5% dextrose
over 4 h, followed by 100 mg/kg IV in 1000 mL 5%
dextrose over 16 h.
Following the administration of these agents, her overall
clinical condition markedly improved over the next 2 days.
On hospital day 11, her rash and lymphadenopathy had
resolved. The patient was discharged home on oral methyl-
prednisolone 50 mg daily for 2 weeks. On a subsequent
outpatient follow-up visit, given the paucity of signs and
symptoms, her methylprednisolone was tapered within 5
days (32 mg on day 1, 16 mg on day 2, 8 mg on day 3, 4 mg
on day 4, and 2 mg on day 5). One month later, her liver
function tests returned to normal levels. Anticonvulsants
were not resumed. To date she remains seizure-free and
asymptomatic. She wears an AHS medical alert bracelet.
Discussion
AHS is a drug-induced, potentially fatal, multiorgan
condition that may develop after the ingestion of certain
anticonvulsants. Common offenders include phenytoin,
carbamazepine, and phenobarbital. Additionally, AHS
cases associated with lamotrigine and oxcarbazepine have
been described (Fervenza et al., 2000; Pastor-Miln et al.,
2003). Cross-sensitivity between causative agents has
been reported to be as high as 80% (Brown et al., 1997).
This condition has an estimated incidence between
1/1,000 to 1/10,000 exposures, although it is thought to
be unrecognized and underreported. It has an autosomal
dominant inheritance pattern; siblings of affected patients
may have an increased susceptibility to develop this condi-
tion. In addition, the African American population is more
frequently affected (Bohan et al., 2007). There is no rela-
tionship between drug serum levels and aggressiveness of
the disease (De Vriese et al., 1995; Mason, 2007). Severe
cases develop multiple organ failure and ultimately death.
Although the exact pathogenesis of AHS remains
unclear, it has been described that aromatic ring-containing
compounds may be metabolized by the hepatic cytochrome
P-450 enzyme system to arene oxide metabolites. Defects
in enzymes required for the detoxification and elimination
of these metabolites have been identified in patients with
AHS (Dwivedi et al., 2004). The resulting accumulation of
arene oxide may trigger various immunopathic phenomena
that include: antigen-hapten complex formation, major
histocompatibility complex activation, and T cell stimula-
tion with subsequent cytokine release (Shear & Spielberg,
1988; Knowles et al., 1999; Krauss, 2006). These meta-
bolites may also establish covalent bonds with cells and
neighboring macromolecules, becoming directly cytotoxic
to various tissues and organs. Oxcarbazepine and lamo-
trigine exact mechanisms of disease remain obscure.
The rationale for suggesting N-AC and IVIG for the
treatment of this syndrome relies on the theoretical syner-
gistic effects of the two agents combined. While the exact
mechanism of action is not fully known, IVIG has been
described as having the ability to form immune complexes
that block immunoglobulin G (IgG) Fc receptors, to
decrease immune-complex-mediated inflammation, to
neutralize autoantibodies, and to attenuate complement-
mediated damage. Eosinophilia and atypical lymphocyto-
sis may be present in AHS; the addition of IVIG may
control B and T cell proliferation and subsequently block
the production of interleukin 5 (IL-5) and eosinophil
maturation (Kazatchkine & Kaveri, 2001; Wu et al.,
2006). Moreover, IVIG appears to block CD95 (Fas), a
keratinocyte cell surface receptor described to play a role
in apoptosis triggering; shown both in vitro and in patients
with TEN (Viard et al., 1998; Mittmann et al., 2006).
The production of free radicals leading to hepatocellu-
lar oxidative damage has been investigated, and a number
of studies have demonstrated the antioxidant role of
N-AC. The use of N-AC has been shown to be particularly
beneficial in acetaminophen-induced liver failure by
repleting hepatic glutathione (James et al., 2003). Gluta-
thione is a molecule involved in multiple detoxification
pathways, including anticonvulsants. Depletion of such
molecule may ultimately result in accumulation of patho-
genic metabolites and potential deleterious effects. We
postulate that this particular therapeutic effect of N-AC
may be extrapolated to AHS, where the conjugation and
elimination pathway of reactive arene epoxide metabolites
may be impaired. Additionally, N-AC may modulate
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hypersensitivity reactions by limiting the production of
inflammatory cytokines and the expression of keratino-
cyte intercellular adhesion molecule-1 (ICAM-1). These
effects may limit the extent of dermatologic and internal
organ compromise seen in AHS.
Moreover, N-AC appears to buffer harmful effects of
metabolites produced by neutrophil myeloperoxidase, an
implicated enzyme in detoxification pathways of aromatic
ring-containing anticonvulsants (De Swert et al., 1984;
Gressier et al., 1994). Furthermore, N-AC has been
described to have antiapoptotic properties by activation of
the Ras-extracellular signal regulated kinase and to inhibit
the inducible form of nitric oxide synthetase from producing
inflammatory cytokines (Bergamini et al., 2001; Rota et al.,
2002). Less known effects of N-AC supplementation
include possible improvement of hepatic blood flow,
increase in cardiac output, and optimization of oxygen deliv-
ery, extraction, and consumption (Harrison et al., 1991;
Sheiner et al., 1992; Agusti et al., 1997; Devlin et al., 1997).
Both IVIG and IV N-AC can have side effects. One of
the most serious adverse effects observed with IVIG is
anaphylaxis. IV N-AC is generally well tolerated, and
adverse effects are infrequently observed in clinical prac-
tice, although cases of tonic–clonic seizures and angioe-
dema have been reported (Ziment, 1988; Redondo et al.,
1997; Simonart et al., 1998; Walsh & Lee, 1999; Tas
et al., 2001).
Immunomodulation poses a theoretical option that may
be beneficial in AHS. It is our hypothesis that ‘‘conven-
tional’’ therapeutic measures failed until the above
described regimen was added. We cannot compare the
described regimen versus monotherapy or the combina-
tion of high-dose steroids. It is unknown whether a differ-
ent initial steroid taper could have prevented the
development of recurrent AHS. It is also uncertain
whether this patient would have recovered without immu-
nomodulation. We suggest that alternative therapeutic
regimens should be given special consideration, especially
in those critical clinical situations in which supportive
measures appear to be unsuccessful.
In conclusion, we present a case of life-threatening AHS
that was successfully treated with a combination of IVIG
and N-AC. While we cannot be certain that one of these
therapies alone may have been effective, we hope to
increase awareness and provide therapeutic options for this
syndrome given its rarity, life threatening features, and
pathophysiologic mechanisms. We encourage future
research in this field in order to elucidate underlying mech-
anisms of injury and to further develop effective treatments
for this entity.
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